A study of xanomeline/trospium for early schizophrenia
Part of Mental health clinical trials.
This study tests a new combination medication (xanomeline/trospium) for people with early schizophrenia who want to switch antipsychotics. The goal is to see if it helps control symptoms and is easier to tolerate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 40 years old
- You have been diagnosed with schizophrenia within the last 5 years and are currently taking a stable dose of one antipsychotic for at least 8 weeks
- You want to switch antipsychotics because the current one isn't controlling symptoms or is causing side effects
- You are not taking two or more antipsychotics, and have not taken clozapine before
- You are not considered treatment-resistant (meaning you haven't failed two adequate trials of different antipsychotics)
- You can get care on an outpatient basis and give informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how satisfied people with schizophrenia are with a new combination medicine called xanomeline and trospium chloride (XT). It aims to understand real-world experiences and benefits of this treatment.
This trial tests whether a new oral medication, KarXT, can help prevent a return of schizophrenia symptoms in people who have been stable on treatment. If you've had a hospital stay in the past year and still have some symptoms, you may be able to join.
This trial looks at how well KarXT works and what side effects it might have when people with schizophrenia switch to it from their current antipsychotic medication. It may be an option for those who have started KarXT recently or who plan to switch from their current treatment.
This study tests a new medicine (KarXT) for schizophrenia, focusing on how it affects urological (bladder and urinary) safety. You'll stop your current antipsychotic and take the study drug to see if it works well and is safe for your urinary system.
This trial tests an experimental medicine, LTX-001, for people with schizophrenia who are currently having a sudden worsening of symptoms. It aims to see if the drug can help reduce these acute symptoms.
This study tests a combination medicine (xanomeline and trospium chloride) to see if it is safe and tolerable over a longer period for children and adolescents with psychiatric disorders, especially those with autism-related irritability. It may help families understand if this treatment can be used beyond the initial study period.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.